Combined Use of Gefitinib and Bevacizumab in Advanced Non-Small-Cell Lung Cancer with <i>EGFR</i> G719S/S768I Mutations and Acquired C797S Without T790M After Osimertinib: A Case Report and Literature Review
Epidermal growth factor receptor (<i>EGFR</i>) tyrosine kinase inhibitors (TKIs) are effective in non-small-cell lung cancer (NSCLC) with sensitizing mutations. However, patients with uncommon <i>EGFR</i> mutations show variable responses, and resistance often develops. The C797S mutation is a commo...
محفوظ في:
| المؤلفون الرئيسيون: | , , , , , , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
MDPI AG
2025-03-01
|
| سلاسل: | Current Oncology |
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://www.mdpi.com/1718-7729/32/4/201 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|